Fujian Cosunter Pharmaceutical Co., Ltd., a prominent player in the health care sector, has been making significant strides in the pharmaceutical industry since its inception in 2001. Based in Fuzhou, China, the company has established itself as a key entity in the research, development, manufacturing, and distribution of pharmaceutical products, particularly focusing on treatments for hepatitis B virus (HBV).

As of September 29, 2025, Fujian Cosunter’s stock closed at 98.91 CNY on the Shenzhen Stock Exchange, reflecting a robust market presence with a market capitalization of approximately 17.74 billion CNY. The company’s stock has experienced notable fluctuations over the past year, reaching a 52-week high of 188.93 CNY on August 18, 2025, and a low of 21.08 CNY on October 10, 2024. These movements underscore the dynamic nature of the pharmaceutical sector and the company’s resilience in navigating market challenges.

Fujian Cosunter’s product portfolio is centered around crude drugs and solid preparations, including tablets, capsules, granules, and medicinal teas. The company’s flagship products, such as Adefovir Dipivoxil and Lamivudine tablets, along with Entecavir and Tenofovir Disoproxil Fumarate capsules, have been pivotal in its growth trajectory. These products are integral to the treatment of HBV, a condition affecting millions globally, thereby positioning Fujian Cosunter as a critical player in addressing a significant public health challenge.

The company’s commitment to innovation and quality is evident in its extensive research and development efforts. By focusing on the development of effective HBV treatments, Fujian Cosunter not only contributes to global health but also strengthens its competitive edge in the pharmaceutical market. The company’s strategic initiatives are likely to drive future growth, as it continues to expand its product offerings and enhance its manufacturing capabilities.

Fujian Cosunter’s presence on the Shenzhen Stock Exchange provides it with a platform to attract investment and foster growth. The company’s financial performance and strategic direction are closely monitored by investors and industry analysts, who recognize its potential to capitalize on the growing demand for HBV treatments.

For stakeholders and interested parties, further information about Fujian Cosunter Pharmaceutical Co., Ltd. and its offerings can be accessed through its official website at www.cosunter.com . As the company continues to innovate and expand its reach, it remains a key entity in the global pharmaceutical landscape, poised for sustained growth and impact in the health care sector.